...
首页> 外文期刊>Biomaterials >Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells
【24h】

Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells

机译:整合素特异性水凝胶可作为恶性B和T细胞的适应性肿瘤类器官

获取原文
获取原文并翻译 | 示例

摘要

Non-Hodgkin lymphomas are a heterogeneous group of lymphoproliferative disorders of B and T cell origin that are treated with chemotherapy drugs with variable success rate that has virtually not changed over decades. Although new classes of chemotherapy-free epigenetic and metabolic drugs have emerged, durable responses to these conventional and new therapies are achieved in a fraction of cancer patients, with many individuals experiencing resistance to the drugs. The paucity in our understanding of what regulates the drug resistance phenotype and establishing a predictive indicator is, in great part, due to the lack of adequate ex vivo lymphoma models to accurately study the effect of microenvironmental cues in which malignant B and T cell lymphoma cells arise and reside. Unlike many other tumors, lymphomas have been neglected from biomaterials-based microenvironment engineering standpoint. In this study, we demonstrate that B and T cell lymphomas have different pro-survival integrin signaling requirements (alpha v beta 3 and alpha 4 beta 1) and the presence of supporting follicular dendritic cells are critical for enhanced proliferation in three-dimensional (3D) microenvironments. We engineered adaptable 3D tumor organoids presenting adhesive peptides with distinct integrin specificities to B and T cell lymphoma cells that resulted in enhanced proliferation, clustering, and drug resistance to the chemotherapeutics and a new class of histone deacetylase inhibitor (HDACi), Panobinostat. In Diffuse Large B cell Lymphomas, the 3D microenvironment upregulated the expression level of B cell receptor (BCR), which supported the survival of B cell lymphomas through a tyrosine kinase Syk in the upstream BCR pathway. Our integrin specific ligand functionalized 3D organoids mimic a lymphoid neoplasm-like heterogeneous microenvironment that could, in the long term, change the understanding of the initiation and progression of hematological tumors, allow primary biospecimen analysis, provide prognostic values, and importantly, allow a faster and more rational screening and translation of therapeutic regimens. (C) 2015 Elsevier Ltd. All rights reserved.
机译:非霍奇金淋巴瘤是B和T细胞起源的淋巴增生性疾病的异质性组,已用化学疗法药物治疗,成功率可变,几十年来几乎没有改变。尽管出现了新型的无化学疗法的表观遗传和代谢药物,但是在一部分癌症患者中,对一些常规和新疗法产生了持久的反应,许多人都对药物产生了抗药性。由于缺乏足够的离体淋巴瘤模型无法准确研究微环境线索(其中恶性B和T细胞淋巴瘤细胞的作用),因此我们对调控耐药性表型和建立预测指标的理解缺乏,这在很大程度上是由于出现并居住。与许多其他肿瘤不同,从基于生物材料的微环境工程的角度来看,淋巴瘤已被忽略。在这项研究中,我们证明B细胞和T细胞淋巴瘤具有不同的生存前整合素信号转导要求(alpha v beta 3和alpha 4 beta 1),并且支持性滤泡树突状细胞的存在对于三维三维扩散的增强至关重要(3D )微环境。我们设计了可适应性的3D肿瘤类器官,它们对B细胞和T细胞淋巴瘤细胞具有独特的整合素特异性粘附肽,从而增强了对化疗药物和新型组蛋白脱乙酰基酶抑制剂(HDACi)的增殖,聚类和耐药性,Panobinostat。在弥漫性大B细胞淋巴瘤中,3D微环境上调了B细胞受体(BCR)的表达水平,这通过上游BCR途径中的酪氨酸激酶Syk支持了B细胞淋巴瘤的生存。我们的整合素特异性配体功能化3D类器官模拟了淋巴样肿瘤样的异质微环境,从长远来看,它可能会改变对血液肿瘤发生和发展的理解,可以进行主要的生物标本分析,提供预后价值,并且重要的是,可以更快地进行以及更合理的治疗方案筛选和翻译。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号